Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody

Dalian University30 enrolled

Overview

to evaluate the prognosis of non-small cell lung carcinoma patients under CIK cellular treatment with PD-1 blocking on top of the standard therapy

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Non-small Cell Lung Cancer

Interventions

CIK cells with PD-1 blockingBIOLOGICAL

CIK cellular therapy with PD-1 blocking

standard lung cancer treamentOTHER

standard non-small cell lung cancer treatment: surgery, chemotherapy

CIK cells without PD-1 blockingBIOLOGICAL

CIK cellular therapy without PD-1 blocking

Eligibility

Sex: ALLMin age: 40 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * non-small cell lung cancer; * more than 50% tumor tissues positive with PD-L1; * EGFR and ALK wild type * no other tumors Exclusion Criteria: * with systematic diseases shortening survival

Outcomes

Primary Outcomes

progression-free survival

Time frame: 5 years

metastasis-free survival

Time frame: 5 years

Central Contacts

haoren wang

CONTACT

86-041162893507 haoren_wang@yahoo.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.